I’m actually Japanese and can’t write English well, so I wrote the comment in Japanese and had GPT-5.1 translate it for me.
What I posted is still my own thinking — I just let the model handle the English part.
Very cool post.. this could be a real game-changer if the signal holds up. The review + early human data on GLP-1 receptor agonists are compelling: beyond metabolic effects, GLP-1R activation seems to modulate core reward circuits (dopamine, GABA, etc.) linked to craving and addiction. At the same time, i would prefer a bit more caution i.e. reality check. Most of the data are still preclinical or from small/short Phase 2 trials; we need larger, longer, and more diverse studies to know who benefits, at what dose, and what the safety/side-effect profile looks like when used for ASUD.
reply